• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    MagicMed Industries: Establishing a Library of Novel Psychedelic Derivatives

    Diana Fernandez
    Mar. 01, 2021 02:44PM PST
    Biotech Investing
    psychedelics

    MagicMed Industries has launched its campaign on the Investing News Network.

    MagicMed Industries is engaging with the psychedelic’s rapid market growth by establishing its flagship molecule derivatives library, the Psybrary™, an essential building block from which industry partners can develop new patented products. The Psybrary™ is a particularly exciting project considering the surge of interest and investment in psychedelics as an alternative mental health therapy in recent years. In 2017, the US Food and Drug Administration (FDA) recognized the potential benefits of MDMA by assigning a Breakthrough Therapy Designation to an MDMA-assisted therapy to treat post-traumatic stress disorder (PTSD).

    The MagicMed team combines synthetic biology and traditional chemistry techniques. This combination has allowed MagicMed to create a large and diverse library of molecules. MagicMed analyzes, catalogues, and stores the molecules to find desired characteristics, such as an improved safety profile.

    MagicMed Industries’ Company Highlights

    • MagicMed Industries is a biotechnology company focused on its flagship Psybrary™ project, a library of novel derivative molecules based on classic psychedelics like psilocybin, DMT, mescaline, ibogaine, MDMA and LSD.
    • The company’s main objective is advancing the discovery and early development of novel drug candidates structurally similar to classic psychedelics.
    • MagicMed has finished it’s initial derivative portfolio based on the structures of psilocybin and N,N-dimethyltryptamine (DMT).
    • MagicMed’s diverse approach to molecule manufacturing, revenue generation and market exposure has reduced the company’s business model risk while positioning it for significant economic growth.

    magicmed industries
    The Conversation (0)

    Go Deeper

    AI Powered
    CSE:XMG

    A Closer Look at Magnesium

    bctx stock

    BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×